DOCSLIB.ORG

In RFX-B-Deficient Cells Through Exogenous Class II Transactivator Partial Rescue of MHC and Related Genes Novel Mutations Withi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In RFX-B-Deficient Cells Through Exogenous Class II Transactivator Partial Rescue of MHC and Related Genes Novel Mutations Withi Novel Mutations Within the RFX-B Gene and Partial Rescue of MHC and Related Genes Through Exogenous Class II Transactivator in RFX-B-Deficient Cells This information is current as of October 1, 2021. Uma M. Nagarajan, Ad Peijnenburg, Sam J. P. Gobin, Jeremy M. Boss and Peter J. van den Elsen J Immunol 2000; 164:3666-3674; ; doi: 10.4049/jimmunol.164.7.3666 http://www.jimmunol.org/content/164/7/3666 Downloaded from References This article cites 58 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/164/7/3666.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 1, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Novel Mutations Within the RFX-B Gene and Partial Rescue of MHC and Related Genes Through Exogenous Class II Transactivator in RFX-B-Deficient Cells1 Uma M. Nagarajan,2* Ad Peijnenburg,2† Sam J. P. Gobin,† Jeremy M. Boss,3,4* and Peter J. van den Elsen3† MHC class II deficiency or bare lymphocyte syndrome is a severe combined immunodeficiency caused by defects in MHC-specific regulatory factors. Fibroblasts derived from two recently identified bare lymphocyte syndrome patients, EBA and FZA, were found to contain novel mutations in the RFX-B gene. RFX-B encodes a component of the RFX transcription factor that functions in the assembly of multiple transcription factors on MHC class II promoters. Unlike RFX5- and RFXAP-deficient cells, trans- fection of exogenous class II transactivator (CIITA) into these RFX-B-deficient fibroblasts resulted in the induction of HLA-DR ␤ Downloaded from and HLA-DP and, to a lesser extent, HLA-DQ. Similarly, CIITA-mediated induction of MHC class I, 2-microglobulin, and invariant chain genes was also found in these RFX-B-deficient fibroblasts. Expression of wild-type RFX-B completely reverted the noted deficiencies in these cells. Transfection of CIITA into Ramia cells, a B cell line that does not produce a stable RFX-B mRNA, resulted in induction of an MHC class II reporter, suggesting that CIITA overexpression may partially override the RFX-B defect. The Journal of Immunology, 2000, 164: 3666–3674. ajor histocompatibility complex class II genes encode indirectly to conserved regulatory elements in the proximal pro- http://www.jimmunol.org/ cell-surface glycoproteins that fulfill a crucial function moter of these genes (reviewed in Refs. 6–10). M in the immune response and in T cell development The conserved S, X (comprising X1 and X2), and Y box DNA (1, 2). The importance of these molecules is illustrated in patients sequence regulatory elements that have been identified in the prox- suffering from MHC class II deficiency or bare lymphocyte syn- imal promoter of MHC class II, class I, and their accessory genes drome (BLS),5 a severe combined immunodeficiency. This dis- are bound by several DNA-binding protein complexes (reviewed ease, which is characterized by an absence of MHC class II ex- in Refs. 3, 6, 7, and 11–14). These include RFX, X2BP (cAMP pression and frequently also by a reduced level of MHC class I response element binding protein; CREB), and NF-Y, which bind expression (3), results in the inability to present antigenic peptides cooperatively to the X1 box (8, 15), X2 box (8, 9, 16, 17), and Y by guest on October 1, 2021 to CD4ϩ T cells for initiation of the immune response. BLS pa- box (18, 19), respectively. Together these proteins are engaged in tients manifest severely impaired humoral and cellular immune the formation of a highly stable multiprotein DNA complex (20– responses, as well as impaired development of CD4ϩ T cells (4, 5) 24). Although individual binding of RFX or X2BP to some of the and therefore are extremely susceptible to many opportunistic in- isotypic MHC class II-conserved elements has been shown to be fections (5). BLS is inherited in an autosomal recessive fashion weak or absent (8, 22), the RFX/X2BP/NF-Y complex is formed and results from mutations in the genes encoding transacting reg- on X-Y DNA of all MHC class II isotypic promoters (22). In a ulatory proteins. These transcription factors are critical to the ex- similar fashion, multiprotein complex formation also occurs on ␤ ␤ pression of MHC class II genes and play an ancillary role in the X-Y DNA of the MHC class I and 2-microglobulin ( 2m) pro- transcriptional control of MHC class I genes by binding directly or moters.6 This complex formation allows the MHC class II isotypes to be regulated in a coordinate fashion. The lack of MHC class II expression and the reduction of MHC class I expression in BLS *Department of Microbiology and Immunology, Emory University School of patient-derived cell lines with defects in one of the RFX sub- Medicine, Atlanta, GA 30322; †Division of Molecular Biology, Department of Im- munohematology and Blood Bank, Leiden University Medical Center, Leiden, The units is attributed to the failure to assemble this complex in vivo Netherlands (25, 26).6 Received for publication October 5, 1999. Accepted for publication January 19, 2000. Formation of this multiprotein complex on X-Y DNA is not The costs of publication of this article were defrayed in part by the payment of page sufficient for activation of MHC class II genes. Activation requires charges. This article must therefore be hereby marked advertisement in accordance the activity of the MHC class II transactivator (CIITA) (27). with 18 U.S.C. Section 1734 solely to indicate this fact. CIITA is believed to act as a transcriptional coactivator through 1 This research was supported by grants from the National Institutes of Health to J.M.B. (GM47310 and AI34000) and The Netherlands Organization for Research to protein/protein interactions with the RFX complex and as such P.J.v.d.E. (Grant 901-09-243). S.J.P.G. is a Fellow of the Royal Netherlands Acad- connects the MHC-specific transcription complex with the basal emy for Arts and Sciences. transcription initiation apparatus (28–30). CIITA has strong trans- 2 U.M.N. and A.P. contributed equally to the content of this manuscript. activation properties that are mediated through its acidic NH2-ter- 3 J.M.B. ans P.vD.E. contributed equally to the supervision of this manuscript. minal domain (31, 32). Whereas CIITA is critical for expression of 4 Address correspondence and reprint requests to Dr. Jeremy M. Boss, Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322. E-mail address: [email protected] 5 Abbreviations used in this paper: BLS, bare lymphocyte syndrome; CREB, cAMP 6 Gobin, S. J. P., M. Van Zutphen, S. D. Westerheide, J. M. Boss, and P. J. van den ␤ ␤ response element binding protein; 2m, 2-microglobulin; CIITA, class II transacti- Elsen. MHC gene transactivation through the SXY regulatory module is controlled by vator; Ii, invariant chain; CAT, chloramphenicol acetyltransferase. a specific enhanceosome. Submitted for publication. Copyright © 2000 by The American Association of Immunologists 0022-1767/00/$02.00 The Journal of Immunology 3667 MHC class II genes, CIITA augments IFN-␥ induction of MHC GAPDH-specific RT-PCR and hybridization was performed as described ␤ previously (44). class I and 2m genes (8–10). Four distinct genetic complementation groups have been de- RNA and DNA hybridization analysis scribed in BLS (A–D) (33), and the genes affected in these comple- mentation groups have been identified. BLS patients of comple- For Figs. 1 and 2, total cellular RNA was prepared using RNAzolB (Cinna/ Biotecx Laboratories, Houston, TX) following the manufacturer’s instruc- mentation group A are defective in CIITA (27, 34). The genes tions. Twenty micrograms of total RNA was separated on an 1.2% agarose affected in groups B, C, and D all encode subunits of the hetero- gel containing 2.2 M formaldehyde, transferred to a Hybond N membrane trimeric phosphoprotein RFX (35). BLS groups B, C, and D are (Amersham), and hybridized using probes that were labeled with 32 defective in RFX-B (also referred to as RFXANK) (36, 37), RFX5 [ P]dCTP by random priming (DuPont-NEN, Brussels, Belgium). Trans- fer and hybridization were performed according to the instructions of the (38, 39), and RFXAP (40, 41), respectively. RFX-B is the smallest manufacturer of the membranes. The human cDNA probes for MHC class ␤ (33 kDa) of the three subunits that constitute the RFX complex I, MHC class II, invariant chain (Ii), 2m, and GAPDH were described (36, 37). Despite evidence demonstrating that RFX-B interacts before (43–46). For Fig. 7, RNA was extracted from cells using the with DNA (42), the protein has no known DNA binding domain RNeasy kit (Qiagen, Valencia, CA). Total RNA (10 ␮g) was used for (36, 37). RFX-B contains three ankyrin repeats that may be im- Northern blot analysis. Random primed RFX-B cDNA (Rediprime II; Amersham) spanning exons 3–10 was used as a probe, and hybridization portant in the formation of the RFX complex and the assembly of was conducted in Ultrahyb (Ambion, Austin, TX).
Load more

Recommended publications
  • IDF Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. FIFTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013 IMMUNE DEFICIENCY FOUNDATION Copyright 2013 by Immune Deficiency Foundation, USA. REPRINT 2015 Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook for Primary Immunodeficency Diseases 5th Edition This publication has been made possible through a generous grant from Baxalta Incorporated Immune Deficiency Foundation 110 West Road, Suite 300 Towson, MD 21204 800-296-4433 www.primaryimmune.org [email protected] EDITORS R. Michael Blaese, MD, Executive Editor Francisco A. Bonilla, MD, PhD Immune Deficiency Foundation Boston Children’s Hospital Towson, MD Boston, MA E. Richard Stiehm, MD M. Elizabeth Younger, CPNP, PhD University of California Los Angeles Johns Hopkins Los Angeles, CA Baltimore, MD CONTRIBUTORS Mark Ballow, MD Joseph Bellanti, MD R. Michael Blaese, MD William Blouin, MSN, ARNP, CPNP State University of New York Georgetown University Hospital Immune Deficiency Foundation Miami Children’s Hospital Buffalo, NY Washington, DC Towson, MD Miami, FL Francisco A.
    [Show full text]
  • IDF Guide to Hematopoietic Stem Cell Transplantation
    Guide to Hematopoietic Stem Cell Transplantation Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation This publication contains general medical information that cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this publication should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment are unique. Copyright 2018 by Immune Deficiency Foundation, USA Readers may redistribute this guide to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation (IDF). If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA, or by telephone: 800-296-4433. For more information about IDF, go to: www.primaryimmune.org. This publication has been made possible through the IDF SCID Initiative and the SCID, Angels for Life Foundation. Acknowledgements The Immune Deficiency Foundation would like to thank the organizations and individuals who helped make this publication possible and contributed to the development of the Immune Deficiency Foundation Guide to Hematopoietic Stem
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • The RFX Complex Is Crucial for the Constitutive and CIITA-Mediated Transactivation of MHC Class I and ␤2-Microglobulin Genes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Immunity, Vol. 9, 531±541, October, 1998, Copyright 1998 by Cell Press The RFX Complex Is Crucial for the Constitutive and CIITA-Mediated Transactivation of MHC Class I and b2-Microglobulin Genes Sam J. P. Gobin,² Ad Peijnenburg,² of the NF-kB/Rel family and are thought to be essential Marja van Eggermond, Marlijn van Zutphen, for both constitutive and cytokine-induced expression Rian van den Berg, and Peter J. van den Elsen* (Girdlestone et al., 1993; Mansky et al., 1994). The ISRE Department of Immunohematology and Blood Bank is bound by factors of the interferon regulatory factor Leiden University Medical Center (IRF) family and mediates the induction of MHC class I 2333 ZA Leiden expression by interferons (Girdlestone et al., 1993). Site The Netherlands a was originally described as being important for the constitutive expression of MHC class I genes (Dey et al., 1992). However, a crucial role in a novel route of Summary HLA class I gene activation mediated by the class II transactivator (CIITA) has recently been attributed to In type III bare lymphocyte syndrome (BLS) patients, site a (Gobin et al., 1997; Martin et al., 1997). Enhancer defects in the RFX protein complex result in a lack of B contains an inverted CCAAT box sequence that plays MHC class II and reduced MHC class I cell surface a role in basal MHC class I gene transcription (Schoneich et al., 1997). In the promoter region of the m gene, expression.
    [Show full text]
  • RFXAP Gene Regulatory Factor X Associated Protein
    RFXAP gene regulatory factor X associated protein Normal Function The RFXAP gene provides instructions for making a protein called RFX associated protein (RFXAP). It primarily helps control the activity (transcription) of genes called major histocompatibility complex (MHC) class II genes. Transcription is the first step in the production of proteins, and RFXAP is critical for the production of specialized immune proteins called MHC class II proteins from these genes. The RFXAP protein is part of a group of proteins called the regulatory factor X (RFX) complex. This complex attaches to a specific region of DNA involved in the regulation of MHC class II gene activity. The RFXAP protein helps the complex attach to the correct region of DNA. The RFX complex attracts other necessary proteins to this region and helps turn on MHC class II gene transcription, allowing production of MHC class II proteins. MHC class II proteins are found on the surface of several types of immune cells, including white blood cells (lymphocytes) that are involved in immune reactions. These proteins play an important role in the body's immune response to foreign invaders, such as bacteria, viruses, and fungi. To help the body recognize and fight infections, MHC class II proteins bind to fragments of proteins (peptides) from foreign invaders so that other specialized immune system cells can interact with them. When these immune system cells recognize the peptides as harmful, they trigger the lymphocytes and other immune cells to launch immune responses to get rid of the foreign invaders. The RFX complex also appears to play a role in the transcription of MHC class I genes, which provide instructions for making immune system proteins called MHC class I proteins.
    [Show full text]
  • Blueprint Genetics Severe Combined Immunodeficiency Panel
    Severe Combined Immunodeficiency Panel Test code: IM0101 Is a 80 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of combined immunodeficiencies. The genes on this panel are included in the Primary Immunodeficiency Panel. About Severe Combined Immunodeficiency Severe combined immunedeficiencies (SCIDs) are a group of primary immunodeficiencies characterized by specific mutations in genes of T and B-lymphocyte systems and leading to little or no immune response. Different subtypes of SCIDs are characterized and subdivided by the presence of circulating T and B cells. T cells are absent or markedly decreased in the most types, but levels of B cells vary. In addition, both of these disease subgroups (T-B+ and T-B-) can occur with or without NK cells. Patients with SCID are susceptible to recurrent infections that can be fatal. The worldwide prevalence of SCID is estimated to be at least 1:100,000 births, while some genetically more homogenous populations may show markedly increased numbers. Mutations in IL2RG are the most common reason for SCIDs, explaining approximately 50% of all cases and close to 100% of X-linked cases. Availability 4 weeks Gene Set Description Genes in the Severe Combined Immunodeficiency Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ADA Severe combined immunodeficiency due to adenosine deaminase AR 49 93 deficiency AK2 Reticular dysgenesis AR 14 17 ATM Breast cancer, Ataxia-Telangiectasia AD/AR 1047 1109 BCL11B Immunodeficiency
    [Show full text]
  • Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SIXTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013, 2019 IMMUNE DEFICIENCY FOUNDATION Copyright 2019 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases 6th Edition The development of this publication was supported by Shire, now Takeda. 110 West Road, Suite 300 Towson, MD 21204 800.296.4433 www.primaryimmune.org [email protected] Editors Mark Ballow, MD Jennifer Heimall, MD Elena Perez, MD, PhD M. Elizabeth Younger, Executive Editor Children’s Hospital of Philadelphia Allergy Associates of the CRNP, PhD University of South Florida Palm Beaches Johns Hopkins University Jennifer Leiding,
    [Show full text]
  • Gastrointestinal Manifestations in Children with Primary Immunodeficiency Diseases
    Egypt J Pediatr Allergy Immunol 2017; 15(1):3-8. Review article Gastrointestinal manifestations in children with primary immunodeficiency diseases Shereen M. Reda Professor of Pediatrics, Ain Shams University, Cairo, Egypt Introduction versus-host-disease and veno-occlusive disease post Primary immunodeficiency (PID) diseases are a hematopoietic stem cell transplantation in certain heterogeneous group of rare genetic disorders that PID diseases2,3. affect the development and function of immune This review focuses on the characteristic chronic cells. To date, more than 150 defects have been GI manifestations that are commonly encountered identified and the number is growing. These in some PID diseases (Table 1). disorders are broadly classified into defects affecting the humoral (B cell) immunity, defects of Severe Combined Immunodeficiency (SCID) the cellular (T cell) immunity or both T cell and B SCID is a heterogeneous group of molecular defects cell, neutrophil and macrophage defects, and in both T- cell and B-cell number and function. defects in the innate immunity. The hallmark According to the presence or absence of T cells, B clinical feature is recurrent and/or severe infections. cells and natural killer (NK) cells, this group is However, some type of immune defect may present broadly classified as T-B+NK+, T-B+NK-, T-B- with autoimmune manifestations, and increased risk NK+, and T-B-NK-3. To date, more than 15 genetic of malignancy in association with their underlying mutations result in the SCID phenotype. The mode immunodeficiency1. of inheritance of these mutations is autosomal In PID diseases, the gastrointestinal (GI) tract is recessive (AR) except the defect in the common the second target organ affected after the respiratory gamma chain which is X-linked and is considered tract.
    [Show full text]
  • Dysregulated Immune System Secondary to Novel Heterozygous Mutation of CIITA Gene Presenting with Recurrent Infections and Syste
    Dysregulated immune system secondary to novel heterozygous mutation of CIITA gene presenting with recurrent infections and Systemic lupus erythematosus Aakash Chandran Chidambaram1, Jaikumar Ramamoorthy2, Sriram Krishnamurthy3, Prabhu Manivannan1, and Pediredla Karunakar1 1Jawaharlal Institute of Postgraduate Medical Education and Research 2Jawaharlal Institute of Post Graduate Medical Education 3Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) June 18, 2020 Abstract The expression of Major Histocompatibility Complex (MHC) molecule is essential for homeostasis of the immune system. Tissue-specific expression of MHC-II is regulated at the level of transcription. The master regulator for transcription of the MHC-II gene is CIITA. Homozygous mutations affecting the CIITA gene results in bare lymphocyte syndrome type-II. The clinical manifestations of heterozygous mutations are not well reported. Hence, this case report aims to provide more insight into the clinical features associated with heterozygous mutations of CIITA. We report a 5-year-old child who had presented with recurrent infections in infancy and systemic lupus erythematosus (SLE) in toddler age. Tables: Nil Figures: 2 Abbreviations MHC Major Histocompatibility Complex SLE Systemic lupus erythematosus ELISA Enzyme Linked Immunosorbant Assay HIV Human Immunodeficiency Virus CVID Common Variable Immunodeficiency EULAR/ACR European League Against Rheumatism/American College of Rheumatology HLA Human Leukocyte Antigen NGS Next Generation Sequencing BLS Bare Lymphocyte Syndrome ANA Antinuclear Antibody Abstract The expression of Major Histocompatibility Complex (MHC) molecule is essential for homeostasis of the immune system. Tissue-specific expression of MHC-II is regulated at the level of transcription. The master regulator for transcription of the MHC-II gene is CIITA. Homozygous mutations affecting the CIITA gene results in bare lymphocyte syndrome type-II1.
    [Show full text]
  • Datasheet: MCA379G Product Details
    Datasheet: MCA379G Description: MOUSE ANTI HUMAN HLA DQ Specificity: HLA DQ Format: Purified Product Type: Monoclonal Antibody Clone: SPV-L3 Isotype: IgG2a Quantity: 0.2 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Flow Cytometry Immunohistology - Frozen Immunohistology - Paraffin ELISA Immunoprecipitation Western Blotting Functional Assays (1) Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls. (1)This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays. Bio-Rad recommend the use of EQU003 for this purpose. Target Species Human Species Cross Reacts with: Pig Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation Purified IgG prepared by ion exchange chromatography from tissue culture supernatant Buffer Solution Phosphate buffered saline Preservative 0.1% Sodium Azide (NaN3) Stabilisers Approx. Protein IgG concentration 1 mg/ml Concentrations Page 1 of 3 External Database Links UniProt: P01909 Related reagents P01906 Related reagents Entrez Gene: 3117 HLA-DQA1 Related reagents 3118 HLA-DQA2 Related reagents Synonyms HLA-DXA Fusion Partners Spleen cells from immunised BALB/c mice were fused with cells of the SP2/0 mouse myeloma cell line.
    [Show full text]
  • Blueprint Genetics Primary Immunodeficiency Panel
    Primary Immunodeficiency Panel Test code: IM0301 Is a 298 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of any type of primary immunodeficiency (PID). About Primary Immunodeficiency Primary immunodeficiencies (PIDs) are a genetically heterogeneous group of diseases. The International Union of Immunological Societies Expert Committee categorizes PIDs into nine different categories: 1) combined immunodeficiencies, 2) combined immunodeficiencies with associated or syndromic features, 3) predominantly antibody deficiencies, 4) diseases of immune dysregulation, 5) congenital defects of phagocyte number, function, or both, 6) defects in intrinsic and innate immunity, 7) autoinflammatory disorders, 8) complement deficiencies and 9) phenocopies of PIDs. Despite a heterogeneous genetic basis, the core symptoms are often very similar complicating the diagnosis. In addition, many PIDs may be included in more than one category. Treatment choice without knowing the specific mutation in the causative gene may therefore be complicated. Also, type and site of and specific organisms causing the infections may help to classify the disease. In addition to immune-related symptoms, many PIDs have non-immune manifestations. The prevalence of individual PIDs have a wide range, but the combined prevalence of all primary immunodeficiencies is reported to be as high as 5-8:10,000. Some recently identified PIDs are extremely rare. Availability 4 weeks Gene Set Description Genes in the Primary Immunodeficiency
    [Show full text]
  • Blueprint Genetics Comprehensive Immune and Cytopenia Panel
    Comprehensive Immune and Cytopenia Panel Test code: IM0901 Is a 642 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of an inborn error of immunity, such as, Primary Immunodeficiency, Bone Marrow Failure Syndrome, Dyskeratosis Congenita, Neutropenia, Thrombocytopenia, Hemophagocytic Lymphohistiocytosis, Autoinflammatory Disorders, Complement System Disorder, Leukemia, or Chronic Granulomatous Disease. This panel includes most genes from Primary Immunodeficiency, Severe Combined Immunodeficiency, Complement System Disorder, Bone Marrow Failure Syndrome, Hemophagocytic Lymphohistiocytosis, Congenital Neutropenia, Thrombocytopenia, Congenital Diarrhea, Chronic Granulomatous Disease, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis Congenita, Autoinflammatory Syndrome, and Hereditary Leukemia Panels as well as many other genes associated with inborn errors of immunity. Please note that unlike our other panels, this panel is on our Whole Exome Sequencing platform and cannot be customized. Pricing may vary from our regular panel pricing. About immunodeficiency and cytopenia disorders There is an enormous amount of phenotypic overlap between immunological and hematological disorders, which makes it challenging to know which of these two systems is not functioning properly. Knowing the underlying genetic cause of a person’s clinical diagnosis, especially immunodeficiency, bone marrow failure, neutropenia, thrombocytopenia, autoinflammatory disease, or bone marrow failure can sometime
    [Show full text]